We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biotage and Shanghai Chempartner Sign Multi-Instrument Deal

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biotage and Shanghai Chempartner Sign Multi-Instrument Deal"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Shanghai Chempartner Co., Ltd. has invested in Biotage SP automated flash instruments and Initiator microwave synthesizers with delivery scheduled over the next 12 months. This is Biotages's largest single order in China at a value of SEK 10m.

Biotage drug discovery instruments and consumables are widely used by medicinal chemists at the pharmaceutical companies, and academic research laboratories. Many multinational pharmaceutical firms, with a long history of using Biotage equipment, have either built new research facilities in China or are outsourcing projects to Chinese CROs.
Chempartner provides contract research services to multinational pharmaceutical firms for production of compound libraries, novel intermediates, and lead optimization.

Chempartner's CEO, Michael Hui, says "We have expanded our operations over the last 4 years to accommodate the rapidly growing trend toward out-sourcing key elements of the drug discovery process. We need the most advanced tools available to create complex new molecules quickly and at high quality. Biotage provides a complete suite of automated tools that improve our workflow and allow our chemists to meet the high-standards of our clients; their instrument performance and proven reliability along with their strong commitment to our success were the key elements of our decision."
"China is the fastest growing market for pharmaceutical contract research. Biotage has been successful in China and this commitment from Chempartner is a strong confirmation of our strategy and focus on drug discovery tools. We will continue to expand our relationships in China and work closely with Chempartner to ensure their success as they implement our equipment and consumables into their research programs." says Torben Jörgensen President and CEO of Biotage AB.